A large majority of people with relapsing-remitting multiple sclerosis (RRMS) who received Tysabri (natalizumab) in a real-world setting experienced no evidence of disease activity for as long as six ...
People with multiple sclerosis (MS) are primarily admitted to the hospital due to urinary tract infections, which indicates that bladder problems need to be better managed in this population, a ...